Evidence map›Paper›PMID 28765892›Full record

ArticleMolecular medicine reports2017

Production of bFGF monoclonal antibody and its inhibition of metastasis in Lewis lung carcinoma.

Yanqing Yang, Zhenming Luo, Yiyang Qin, Yu Zhou, Longcai Gong, Jianfang Huang, Hong Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Biphasic Effects of bFGF Blockade on Lung Cancer Cell Invasion.Doklady. Biochemistry and biophysics · 2025
    Article
  2. Pharmacological and Biological Targeting of FGFR1 in Cancer.Current issues in molecular biology · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yanqing YangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Zhenming LuoGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Yiyang QinGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Yu ZhouDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94122, USA.
Longcai GongGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Jianfang HuangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Hong WangGuangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Biomedicine Translational Institute, Jinan University, Guangzhou, Guangdong 510640, P.R. China.
Jinan University · CNUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor 1 (FGFR1) are associated with drug resistance in lung cancer. In the present study, mouse monoclonal antibodies (mAb) against human bFGF, targeting the binding site of bFGF with FGFR1 were produced, and the antitumor activity and inhibition of metastasis was studied in Lewis lung carcinoma (LLC). A total of four hybridoma cell strains that stably secreted bFGF mAb were obtained. mAbE12 was selected as the most effective for use in the following studies, with a relative affinity constant of 5.66x108 l/mol. mAbE12 was demonstrated to inhibit cell proliferation and tumor growth in vitro and in vivo. Furthermore, mAbE12 blocked migration and metastasis of LLC cells in vitro and in vivo. This occurred due to a mAbE12‑induced upregulation of E‑cadherin expression through the protein kinase B‑glycogen synthase kinase 3 β‑Snail pathway. These results suggested that mAbE12 may be a potential antibody for the treatment of lung cancer.

Indexed as

Antibody FormationHybridomasAnimalsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBinding SitesCarcinoma, Lewis LungCell Line, TumorFibroblast Growth Factor 2MaleMiceModels, MolecularMolecular ConformationProtein BindingXenograft Model Antitumor AssaysAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalFibroblast Growth Factor 2

Identifiers

PMID28765892
PMCPMC5646982
OpenAlexW2740185124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.